ATLANTA (Reuters) - Adding a drug that lowers blood fats known as triglycerides to cholesterol-fighting statins provided no additional protection from heart attack, stroke and death from heart disease in patients with Type 2 diabetes, according to data from a large study. The study run by the National Institutes of Health, dubbed Accord, aimed to see if the dual-drug therapy could ...

Diabetics who seek to aggressively lower their blood pressure and cholesterol are not reducing their risk of a heart attack and could suffer negative side effects, a study released Sunday said. The results of the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial appear to repudiate years of medical advice for type-2 diabetics who face a high ...

Key results from a landmark federal study are in, and the results are disappointing for diabetics: Adding drugs to drive blood pressure and blood-fats lower than current targets did not prevent heart problems, and in some cases caused harmful side effects. A decade ago, the federal ...

ATLANTA (Reuters) - Adding a triglyceride-lowering drug to cholesterol-fighting statins provided no additional protection from heart attack, stroke and death from heart disease in patients with Type 2 diabetes, according to data from a large study. The study run by the National Institutes of Health, dubbed Accord, aimed to see if the dual-drug therapy could reduce cardiovascular events in diabetes patients ...